You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 9, SEPTEMBER 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Comparison of Gemfibrozil and Lovastatin in Patients With High Low-Density Lipoprotein and Low High-Density Lipoprotein Cholesterol Levels

James M. McKenney, PharmD; Michael D. Barnett, PharmD; Jackson T. Wright, Jr, MD, PhD; Jack P. Proctor, MD

Arch Intern Med. 1992;152(9):1781-1787.


Abstract

Background.—
The efficacy of gemfibrozil and lovastatin in the treatment of patients who have an elevated low-density lipoprotein cholesterol (LDL-C) level and a low high-density lipoprotein cholesterol (HDL-C) level was compared.

Methods.—
After at least 6 weeks of a choleserol-lowering diet, 17 patients who had a mean baseline LDL-C level above 4.14 mmol/L (160 mg/dL) and an HDL-C level below 1.03 mmol/L (40 mg/dL) received gemfibrozil 600 mg twice daily and lovastatin 20 mg twice daily each for 6 weeks according to a randomized, crossover, double-blind research design.

Results.—
Lovastatin and gemfibrozil reduced LDL-C levels 34% and 9% and raised HDL-C levels 15% and 18%, respectively.

Conclusions.—
Lovastatin is more effective in lowering LDL-C levels and is as effective as gemfibrozil in increasing HDL-C levels in these patients.

(Arch Intern Med. 1992;152:1781-1787)



Author Affiliations

From the Schools of Pharmacy (Drs McKenney and Barnett) and Medicine (Drs Wright and Proctor), Medical College of Virginia, Virginia Commonwealth University, Richmond. Dr Barnett is now with the US Air Force, Department of Pharmacy, KTTC Medical Center, Keesler Air Force Base, Miss. Dr Wright is now with the Division of Endocrinology and Hypertension, Case Western Reserve University, Cleveland, Ohio.


Footnotes

Accepted for publication January 24, 1992.

The voluntary, fully informed consent of the subjects used in this research was obtained as required by the AFR 169-6. The views in this article do not reflect the official policy or position of the Department of Defense or the US Government.

Reprint requests to PO Box 533, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 (Dr McKenney).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.